Endeavor Venture Funds and Keiretsu Forum Forge Strategic Alliance to Enhance Early-Stage Investment Opportunities
2024年7月2日 - 8:05PM
Endeavor Venture Funds and Keiretsu Forum Mid-Atlantic, South-East,
and Texas announce a key strategic alliance aimed at increasing
investment opportunities in remarkable healthcare and life science
companies and developing a systematic funding process for $1-5MM
early-stage investment rounds.
This pivotal agreement will leverage both entities' combined
expertise, networks, and resources to enhance the life science
startup ecosystem and drive go-to-market growth strategies for the
most promising companies and talented founders.
Strengthening Startup Ecosystems
Endeavor Venture Funds and Keiretsu Forum's partnership promises
unparalleled benefits to startups, investors, and the broader
healthcare community.
"This partnership with Endeavor Venture Funds strengthens our
commitment to scaling pioneering startups," remarked Barry Etra,
Director of Entrepreneurial Services at Keiretsu Forum
Mid-Atlantic, South-East, and Texas. "Our collective networks and
robust resources, including rigorous due diligence processes and
strategic mentorship, provide startups with essential capital,
expertise, and guidance crucial for sustained growth and
success."
Dr. Martin Alexander Gershon, Managing Partner at Endeavor
Venture Funds, emphasized that "95% of startups fail in part due to
a combination of lack of sustained funding and strategic guidance.
Keiretsu Forum is one of the few angel groups with the real world
experience and investment track record to effectively support
early-stage companies beyond the Seed Stage through multiple rounds
of funding. And Endeavor provides a deep network of C-Suite leaders
and strategic partners that help founders grow, scale and
commercialize.”
“Keiretsu and Endeavor have been building this opportunity over
the past two years, and we feel strongly that our exclusive
collaboration will provide startups with the support they need to
focus on driving their innovations and growth," Gershon
continued.
Key Benefits for Stakeholders
For Life Science Startups:
- Accelerated Growth: Access to a vast network
of investors and industry experts who have experience and expertise
in the life science space to speed up growth and innovation.
- Focused Support: More efficient time spent on
fundraising, allowing founders to concentrate on their core
business activities.
- Rigorous Due Diligence: Both entities are
known for their thorough due diligence processes, ensuring that
investment decisions are well-informed and based on robust
analysis.
For Investors:
- Enhanced Deal Flow: Improved access to
high-quality investment opportunities informed by and with Endeavor
looking toward late rounds.
- Expert Insights: Benefit from the collective
experience and knowledge of seasoned professionals in the venture
capital space.
- Co-Investment Potential: Deal sizes
typically range from $1 to $5 million, ample co-investment
opportunities allow for larger funding rounds and better support
for portfolio companies.
For the Regions Involved:
- Economic Growth: By facilitating efficient
navigation from the Seed Stage to later funding rounds, the
alliance will contribute to early-stage growth in the regions,
supporting innovation and job creation.
- Innovation Hub:
Strengthen the regions' positions as leading hubs for med tech,
pharma and other life science innovations.
For more information about the strategic alliance and investment
opportunities, please contact:
Barry EtraKeiretsu
ForumBetra@KeiretsuForum.net
Dr. Martin Alexander GershonEndeavor Venture
FundsMartinalexander@gershoncapital.com
Dr. Martin Alexander Gershon, MD, JD, MPH is the Managing
Partner and CIO of Endeavor Life Sciences Venture Funds and Venture
Studio, Senior Executive Investor in Residence for Healthcare at
Techstars, and Advisor to the White House Moonshot CancerX
Accelerator Program.
He has been honored by Standard and Poor’s as a designated Top
100 “Healthcare Industry Leader”, recognized by Linkedin as a “Top
Voice” in Venture Capital and Entrepreneurship, is an award winning
Google Scholar in Entrepreneurship, the Host of the popular
BetterHealth Webinar Series, contributing writer for Fast Company
on healthcare venture capital and entrepreneurship, and has been
featured on CNBC and in numerous conferences and publications as
one of the leading healthcare investors, strategists, futurists in
the commercialization of healthcare innovation, always “skating to
where the puck is going, not where it is.”
About Endeavor Venture Funds: Endeavor Venture
Funds is a leading healthcare and life sciences venture capital
firm, media company, and strategic advisor for Fortune 500
companies and high growth companies. Founded in 1999, Endeavor has
invested in over 100 groundbreaking companies in three funds, with
a focus on disruptive technologies and scalable commercial
potential.
Over the past 25 years Dr. Gershon has built Endeavor Venture
Funds into a thriving ecosystem of partnerships in Biopharma,
Biotech, Healthtech, Medtech, Hospitals, Academic Medical Centers,
and Venture Capital, that has established a deep network of C-Suite
thought leaders who help guide Endeavor to prescient, future facing
investments and as well advise large industry and emerging startup
clients on how to prepare now for the future ahead.
About Keiretsu Forum: Keiretsu Forum is the
world’s largest private equity angel investment network, with over
2,000 accredited investors across 34 North American and 23
international chapters. The forum has invested over $1 billion in
early-stage companies in the past 23 years, covering diverse
sectors such as technology, life sciences, fintech, and sustainable
technologies.
MEDIA CONTACT:Cindi Sutera,
610-613-2773CindiS@AMSCommunications.net